ProteinQure Analysis: $16M Raised
What is ProteinQure?
ProteinQure designs novel exotic peptides using atomic-level simulations and AI to enable precise tissue-specific delivery of therapeutics. Their proprietary ProteinStudio™ platform combines molecular simulations with custom AI models on petascale supercomputers. The company has advanced PQ203 into a Phase I clinical trial for advanced solid tumors.
Location
Toronto, Canada
Employees
11-50
Founded
2017
Funding Status
Series A
Product Features & Capabilities
- ProteinStudio™ AI platform for de novo peptide design
- PQ203 peptide-drug conjugate in Phase I clinical trial for advanced solid tumors
- Tissue-specific delivery system targeting SORT1 receptor in cancer cells
Use Cases
Design tissue-specific peptides for delivery to triple-negative breast cancer cells; Deliver cytotoxic agents to tumor cells via SORT1 receptor-mediated endocytosis; Test therapeutic payloads including radioisotopes and oligonucleotides in preclinical models; Develop blood-brain barrier shuttle systems for neurodegenerative diseases
Other Considerations
First patient dosed in Phase I clinical trial of PQ203 in advanced metastatic cancer; Validated by AstraZeneca and UHN Princess Margaret Cancer Centre; Partnerships with pharma and academic research institutions; Proprietary ProteinStudio™ platform with petascale computing capabilities
See something that needs updating? Suggest edits to this profile.